Pancreatic Ductal Adenocarcinoma Pipeline Analysis, 2025 By Delveinsight Cardiff Oncology, XOMA, Alphamab, Cantargia, Renovorx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharm

(MENAFN- GetNews)


"Pancreatic Ductal Adenocarcinoma Pipeline Analysis"DelveInsight's,“Pancreatic Ductal Adenocarcinoma - Pipeline Insight, 2025,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Pancreatic Ductal Adenocarcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

According to DelveInsight, over 80 companies are actively developing more than 80 therapies for Pancreatic Ductal Adenocarcinoma.

Pancreatic Ductal Adenocarcinoma Overview:

Pancreatic ductal adenocarcinoma (PDAC) is among the most aggressive cancers, with a 5-year survival rate below 10%. Most patients are diagnosed at advanced, locally unresectable, or metastatic stages. The poor prognosis is driven by the disease's complex, multifactorial nature. Early detection is difficult, as symptoms often appear only after the cancer has progressed and spread. Treatment is further complicated by genetic and cellular factors, with significant tumor mutations causing gene instability that promotes tumor growth and therapy resistance.

Download our report @

"Pancreatic Ductal Adenocarcinoma Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Pancreatic Ductal Adenocarcinoma Therapeutics Market.

Key Takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report

DelveInsight's Pancreatic Ductal Adenocarcinoma (PDAC) pipeline report highlights a dynamic landscape with over 80 companies actively developing more than 80 therapies for PDAC.

Recent regulatory developments include:

• March 26, 2025: FDA approval of cabozantinib for patients with pancreatic and extra-pancreatic neuroendocrine tumors, based on Phase 3 CABINET study data.

• December 4, 2024: FDA approval of zenocutuzumab for NRG1 fusion-positive non-small cell lung cancer and pancreatic adenocarcinoma.

• June 2024: FDA granted Fast Track designation to IBI343 for advanced or metastatic PDAC.

Key players advancing PDAC therapies include Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte, I-Mab Biopharma, Medicenna Therapeutics, Tarveda Therapeutics, and others. Promising pipeline candidates in various stages of development include Onvansertib, Nadunolimab, Zimberelimab, among others.

Pancreatic Ductal Adenocarcinoma Pipeline Analysis

The Pancreatic Ductal Adenocarcinoma pipeline insights report 2025, provides insights into:

• Provides comprehensive insights into key companies developing therapies in the Pancreatic Ductal Adenocarcinoma Market.

• Categorizes Pancreatic Ductal Adenocarcinoma therapeutic companies by development stage: early, mid, and late-stage.

• Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

• Reviews emerging Pancreatic Ductal Adenocarcinoma drugs under development based on:

  • Stage of development

  • Pancreatic Ductal Adenocarcinoma Route of administration

  • Target receptor

  • Monotherapy vs. combination therapy

  • Pancreatic Ductal Adenocarcinoma Mechanism of action

  • Molecular type

• Offers detailed analysis of:

  • Company-to-company and company-academia collaborations

  • Pancreatic Ductal Adenocarcinoma Licensing agreements

  • Funding and investment activities supporting future Pancreatic Ductal Adenocarcinoma market advancement.

Request for a sample report @

Pancreatic Ductal Adenocarcinoma Emerging Drugs

• Onvansertib: Cardiff Oncology

• Nadunolimab: Cantargia

• Zimberelimab: Arcus Biosciences

Pancreatic Ductal Adenocarcinoma Companies

More than 80 companies are developing therapies for Pancreatic Ductal Adenocarcinoma, with XOMA among those advancing candidates into the Phase III stage.

DelveInsight's report covers around 140+ products under different phases of Pancreatic Ductal Adenocarcinoma clinical trials like

• Pancreatic Ductal Adenocarcinoma Late stage Therapies (Phase III)

• Pancreatic Ductal Adenocarcinoma Mid-stage Therapies (Phase II)

• Pancreatic Ductal Adenocarcinoma Early-stage Therapies (Phase I)

• Pancreatic Ductal Adenocarcinoma Pre-clinical and Pancreatic Ductal Adenocarcinoma Discovery stage Therapies

• Pancreatic Ductal Adenocarcinoma Discontinued & Inactive Therapies

Pancreatic Ductal Adenocarcinoma pipeline report provides the Pancreatic Ductal Adenocarcinoma therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Pancreatic Ductal Adenocarcinoma Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Pancreatic Ductal Adenocarcinoma Therapies and Key Pancreatic Ductal Adenocarcinoma Companies: Pancreatic Ductal Adenocarcinoma Clinical Trials and recent advancements

Pancreatic Ductal Adenocarcinoma Pipeline Therapeutic Assessment

. Pancreatic Ductal Adenocarcinoma Assessment by Product Type

. Pancreatic Ductal Adenocarcinoma By Stage

. Pancreatic Ductal Adenocarcinoma Assessment by Route of Administration

. Pancreatic Ductal Adenocarcinoma Assessment by Molecule Type

Download Pancreatic Ductal Adenocarcinoma Sample report to know in detail about the Pancreatic Ductal Adenocarcinoma treatment market @ Pancreatic Ductal Adenocarcinoma Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Pancreatic Ductal Adenocarcinoma Current Treatment Patterns

4. Pancreatic Ductal Adenocarcinoma - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Pancreatic Ductal Adenocarcinoma Late-Stage Products (Phase-III)

7. Pancreatic Ductal Adenocarcinoma Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Pancreatic Ductal Adenocarcinoma Discontinued Products

13. Pancreatic Ductal Adenocarcinoma Product Profiles

14. Pancreatic Ductal Adenocarcinoma Key Companies

15. Pancreatic Ductal Adenocarcinoma Key Products

16. Dormant and Discontinued Products

17. Pancreatic Ductal Adenocarcinoma Unmet Needs

18. Pancreatic Ductal Adenocarcinoma Future Perspectives

19. Pancreatic Ductal Adenocarcinoma Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Pancreatic Ductal Adenocarcinoma Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

MENAFN03092025003238003268ID1110013829